Revvity Ro 15-1788, -, 250uCi (9.25MBq)

250µCi quantities of Ro 15-1788, [N-Methyl-³H]-, are available for research. Ro 15-1788 acts as a selective benzodiazepine antagonist. It is used to treat benzodiazepine overdoses and reverse anesthesia.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET757:

1. Benke D, Cicin-Sain A, Mertens S, Mohler H. Immunochemical identification of the alpha 1- and alpha 3-subunits of the GABAA-receptor in rat brain. J Recept Res. 1991;11(1-4):407-24.
2. Goeders, N., Kuhar, M.J. Benzodiazepine receptor binding invivo with [3H]-Ro 15-1788, Life Sciences, Volume 37, Issue 4, 1985, Pages 345-355.